

Invited Article

Tissue engineering approaches for the construction of a completely autologous tendon substitute

Bassetto Franco, Vindigni Vincenzo, Dalla Vedova Alessandro, Carolin Tonello¹, Giovanni Abatangelo¹, Francesco Mazzoleni

Clinic of Plastic Surgery, Department of Medical and Surgical Specialities, ¹Department of Histology, Microbiology and Medical Biotechnology, University of Padova, Padova, Italy

Address for correspondence: Dr. Franco Bassetto, Clinic of Plastic Surgery, University of Padova, Via Giustiniani 2, 35100 Padova, Italy.
E-mail: franco.bassetto@unipd.it

ABSTRACT

Tissue engineering is a multidisciplinary field that involves the application of the principles and methods of engineering and life sciences towards i) the fundamental understanding of structure-function relationships in normal and pathological mammalian tissues and ii) the development of biological substitutes that restore, maintain or improve tissue function. The goal of tissue engineering is to surpass the limitations of conventional treatments based on organ transplantation and biomaterial implantation. The field of tendon tissue engineering is relatively unexplored due to the difficulty in *in vitro* preservation of tenocyte phenotype. Only recently has mechanobiology allowed us to gain a better understanding of the fundamental role of *in vitro* mechanical stimuli in maintaining the phenotype of tendinous tissue. This review analyzes the techniques used so far for *in vitro* regeneration of tendinous tissue.

KEY WORDS

Biomaterials, bioreactor, mechanobiology, tendon, tissue engineering

INTRODUCTION

Tendons are soft connective tissues, which connect muscle to bone and form a musculo-tendinous unit, whose primary function is to transmit tensile loads generated by muscles to move and stabilize joints. The biomechanical properties of tendons can be attributed to the highly defined organization of their extracellular matrix (ECM). ECM of tendons is primarily composed of collagen I, and is organized in a hierarchy of bundles that are aligned in a parallel manner in a proteoglycan matrix. Tendon injuries produce considerable morbidity, and the disability that they cause may last for several months despite what is considered appropriate management. The basic cell biology of tendons is still not fully understood, and the management of tendon injury poses

a considerable challenge for clinicians. After an injury, the healing process in tendons results in the formation of a fibrotic scar. The structural, organizational, and mechanical properties of this healed tissue are insufficient as tendons possess a limited capacity to regenerate.^[1,2]

Adhesion formation after intrasynovial tendon injury poses a major clinical problem. Disruption of the synovial sheath at the time of the injury or surgery allows granulation tissue and fibroblasts from the surrounding tissue to invade the repair site. Exogenous cells predominate over endogenous tenocytes, allowing the surrounding tissue to attach to the repair site, resulting in adhesion formation. Despite remodeling, the biochemical and mechanical properties of healed tendon tissue never match those of intact tendon. In

a study of transected ovine Achilles tendons that had spontaneously healed, the rupture force was found to be only 56.7% of the normal force after twelve months. One possible reason for this is the absence of mechanical loading during the period of immobilization.^[1,2] It is well demonstrated that mechanical loading plays a central role in tenocyte proliferation and differentiation, and that the absence of mechanical stimuli leads to a leak of cellular phenotype.^[1,2] While certain tendons can be repaired by suturing the injured tissue back together, some heal poorly in response to this type of surgery, necessitating the use of grafts.^[3] Unfortunately, finding suitable graft material can be problematic. Autografts from the patient may result in donor site morbidity, while allografts from cadavers may cause a harmful response from the immune system besides also being limited in supply. In both cases, the graft often does not match the strength of the undamaged tissue.^[4] The loss of mechanical properties is mainly due to a distorted ECM composition and an architectural misalignment of collagen fibrils in the scar tissue.

For this reason, obtaining tendinous tissue through tissue engineering approaches becomes a clinical necessity. Tissue engineering is a multidisciplinary field that involves the application of the principles and methods of engineering and life sciences towards i) the fundamental understanding of structure-function relationships in normal and pathological mammalian tissues and ii) the development of biological substitutes that restore, maintain or improve tissue function. The goal of tissue engineering is to surpass the limitations of conventional treatments based on organ transplantation and biomaterial implantation. It has the potential to produce a supply of immunologically tolerant, 'artificial' organs and tissue substitutes that can grow within the patient. This should lead to a permanent solution to the damage caused to the organ or tissue without the need for supplementary therapies, thus making it a cost-effective, long-term treatment. Tissue engineering uses different biomaterials, carrier cells and/or bioactive factors to stimulate tissue regeneration. Nowadays, there are many tissue engineering approaches. The earliest clinical application of human cells in tissue engineering (in 1980) was for skin tissue using fibroblasts, and keratinocytes, on a scaffold. During the last 30 years, many innovative approaches have been proposed to reconstruct different tissues: skin, bone, and cartilage. The field of tendon tissue engineering is relatively unexplored due to the difficulty in *in vitro* preservation of tenocyte phenotype,

and only recently has mechanobiology allowed a better understanding of the fundamental role of *in vitro* mechanical stimuli in maintaining the phenotype of tendinous tissues. Tendon tissue engineering requires a scaffold that functions as a temporary structure to support initial tissue growth. Scaffolds can improve tendogenesis allowing cell proliferation, ECM production and finally, organizing the matrix into functional tendon tissue. Moreover, tendon regeneration could be stimulated through approaches such as the use of growth factors and gene therapy, as well as by *in vitro* mechanical forces. This review analyzes the techniques used so far for the *in vitro* regeneration of tendinous tissues, and discusses strategies for the improvement of the same.

Scaffold materials used in tendon tissue engineering

Recreating a scaffold appropriate for tendon tissue engineering is difficult because of the particular micro-architecture, both of collagen fibres and of ECM molecules. It is clear that the resistance and elasticity of tissues depend on these parameters due to which, competent scaffolding materials are needed. Biomaterials should protect the cells and new tissue from strong forces, while allowing graded exposure to loading at later points in time. This will allow the tissue to develop more naturally and function more efficiently.^[5] There are many scaffold materials, both natural and synthetic. Natural scaffolds are composed of collagen,^[6,7] porcine small intestine submucosa,^[8,9] chitosan-based scaffolds,^[10-12] silk fibers,^[13-15] semitendinosus tendon^[16] and fibronectin/fibrinogen fibres.^[17] In addition to these natural scaffolds, there are a large number of synthetic scaffolds developed for tendon tissue engineering. The most commonly used synthetic scaffolds are made of poly-lactic acid (PLA)^[11,18-20] and poly lactic-coglycolic acid (PLGA).^[18,21,22]

Usually, a 3D scaffold housing a specific cell type has to be able to be directed to form tendon/ligament tissue. As compared to 2D culture, 3D culture offers the advantage of more closely recreating the spatial organization of native tissue.^[23] There are many considerations that should be taken into account when engineering tendon or ligament tissues. The scaffold should encourage cellular recruitment and tissue ingrowth. Early in the repair process, the scaffold should maintain its mechanical and architectural properties to protect cells and the new, growing tissue from strong forces and early inflammatory events. Subsequently, the scaffold should be gradually reabsorbed allowing a controlled

exposure of the regenerating tissue to the local cellular, biochemical and mechanical environment. This will allow the tissue to develop more naturally and function more efficiently. In order to avoid stress shielding, the scaffold should ideally degrade at the same rate that the new tissue is created. In order to ensure final clinical use, neither the scaffold nor its degradation products should be harmful to the surrounding tissue and they should not result in unresolved inflammation or other deleterious biological responses. In response to these stringent and varied criteria, a number of scaffold materials, both natural and synthetic, have been examined. Collagen, the most prevalent structural protein in the human body, is a natural scaffold material for ligament and tendon replacement. Cells cultured in collagen gels produce extracellular matrix and align longitudinally with the long axis of the tissue equivalent, thereby mimicking cell alignment in ligaments *in vivo*.^[4,24] Fibroblasts seeded in collagen gels change their shape and orientation over time^[24-27] and these organizational changes have been correlated with cell proliferation, protein synthesis, and matrix morphogenesis.^[28-30] Fibroblast-seeded collagen scaffolds have been investigated with regard to their ability to accommodate cell attachment, proliferation, and differentiation.^[4,24,31,32] An *in vivo* study showed that fibroblast-seeded collagen scaffolds were viable for at least eight weeks after reimplantation into donor rabbits.^[33,34] In another study, a tissue-engineered, ligament-like structure was derived from Anterior Cruciate Ligament (ACL) fibroblasts seeded on a collagen scaffold that was anchored to bone, to facilitate implantation.^[4] Elongation of the structure by tension induced a parallel orientation of type I collagen fibers, and this organization was progressively modulated by the fibroblasts seeded into the structure and by the *in vitro* application of tension during its development. Knitted Dacron scaffolds seeded with canine fibroblast cells demonstrated a more uniform and abundant encapsulation with connective tissue than unseeded scaffolds.^[33] These encouraging cellular results lay the foundation for the increasingly challenging goal of improving the *in vivo* mechanical strength to the level of functional ligaments or tendons. Fibres of collagen or degradable polymers of PLGA and PLA can be crosslinked, woven, or braided to increase the mechanical strength of the resulting tissue-engineered tendons and ligaments.^[32,34-40] Fibroblasts have been shown to attach to and function on collagen fibres or PLGA scaffolds in *in vitro* studies, and fibroblast-seeded collagen fiber scaffolds have shown promising results in implantation studies.^[31,32,41] Silk protein-based matrices

have been investigated for ACL tissue engineering because of their interesting mechanical properties as well as their biocompatibility and biodegradability.^[42,43] A silk fibre matrix has promising mechanical properties (tensile strength, stiffness, yield point, and elongation to failure) comparable to those of human ACL.^[43] *In vitro* data demonstrate that the silk matrix provides sufficient support for the attachment, proliferation, and differentiation of human Mesenchymal Stem Cells (MSCs). The fibrous scaffold was covered with a uniform cell sheet and cell-associated extracellular matrix after 21 days with few changes in the tensile strength of the fibre matrix. In an *in vivo* approach, a surgically created gap Medial collateral ligament (MCL) injury in rabbits was healed by using porcine small intestinal submucosa as a collagen scaffold.^[44]

Cells

Multiple cell types have been seeded within scaffolds in an effort to stimulate cell-mediated tissue regeneration. The most common cell types employed are fibroblasts, tenocytes and mesenchymal stem cells/marrow stromal cells (MSCs).^[5] The main cell type found in tendon tissue is the fibroblast, which is responsible for secreting and maintaining the extracellular matrix. Hence, fibroblasts are the predominant cell type used for tissue engineering applications.^[5] Two different fibroblast populations can be found in the tendon: the elongated tenocytes and the ovoid-shaped tenoblasts.^[45] Elongated tenocytes proliferate well in culture and have optimal morphology in terms of expression of collagen type 1, which is a major component of normal tendons.^[45] Tendon cells are usually isolated from human tendon samples by tissue dissociation techniques.^[46-48] After two or three cell culture passages and before they lose their phenotype, they are seeded into collagen gels or into scaffolds at an appropriate cell density (10^6 cells/mL).^[46-48] Several *in vivo* and *in vitro* studies have showed the role of MSCs obtained from different human tissues (mainly bone marrow and adipose tissues) in tendon engineering.^[46,49,50] MSCs can be stimulated to differentiate into fibroblasts when exposed to mechanical stress,^[51] and their rates of proliferation and collagen excretion have been shown to be higher than those of fibroblasts, so they may be a viable alternative to fibroblasts.^[45]

Kall and colleagues^[52] from Hanover Medical School, investigated techniques using mesenchymal stem cells for *in vitro* tendon engineering using a collagen type I gel influenced by cyclic stretching. Tendon substitutes were created by dispersing human mesenchymal stem

cells in a collagen type I gel, followed by polymerization in glass cylinders with defined measurements.^[52] A bioreactor was fabricated to expose tissue engineered tendons to cyclic loading for three weeks. This was a fascinating study and demonstrated histologically that the stretched constructs showed longitudinally oriented spindle-shaped cells with an organized matrix and parallel collagen fibres and increased mRNA syntheses of collagen type I, type III, and fibronectin.^[52] Biomechanical studies will demonstrate whether these constructs have any clinical application. Kryger *et al.*^[53] compared tenocytes and mesenchymal stem cells for use in flexor tendon tissue engineering. They studied four candidate cell types for use in reseeding acellularised tendon constructs. Specifically, they compared epitenon tenocytes, tendon sheath fibroblasts, bone marrow-derived mesenchymal stem cells (BMSCs), and adipoderived mesenchymal stem cells (ASCs) with respect to their *in vitro* growth characteristics, senescence and collagen production, as well as the viability of reseeded constructs.^[53] They also studied the *in vitro* viability of tendon constructs after reseeding and after *in vivo* implantation in a clinically relevant model of rabbit flexor tendon grafting. Results showed that epitenon tenocytes, tendon sheath cells, bone marrow and adipoderived stem cells have similar growth characteristics and can be used to successfully reseed acellularized tendon grafts.^[53] Constructs using the four cell types were also successfully implanted *in vivo* and showed viability after six weeks following implantation.^[53] The most relevant novel finding is that adipo-derived mesenchymal stem cells showed higher proliferation rates at later passages when compared with epitenon tenocytes. ASCs have been shown to have multipotency and may be driven toward tenocyte differentiation when seeded into tendon constructs and exposed to the appropriate environment and mechanical forces.^[53] As confirmed by immunocytochemistry analysis, these stem cells also produce collagen, suggesting that they would contribute to *in vivo* tendon matrix remodeling. In conclusion, these results suggest that ASCs have a practical advantage when compared with epitenon tenocytes and sheath fibroblasts, given that it is easier to harvest large amounts of fat tissue.

Local delivery of growth factors

In vitro cell proliferation and differentiation require an intake of ions and nutrients from the culture medium. However, to obtain specific phenotype expression and proper cell differentiation, several biochemical factors

such as cytokines and growth factors, must be added to the culture medium.^[46,54] The main growth factors that affect the growth and differentiation of ligament and tendon tissues include fibroblast growth factor (FGF), platelet-derived growth factor-BB (PDGF-BB), epidermal growth factor (EGF), insulin-like growth factor (IGF)-1 and members of the transforming growth factor- β (TGF- β)/bone morphogenetic proteins (BMPs) family.^[46,55,56] Many of these growth factors are physiologically released at the site of injury and are able to stimulate cell proliferation, migration, differentiation and matrix synthesis.^[55] Direct injection of recombinant FGF into injured rat patellar tendons increases cell proliferation and Type III collagen expression.^[55,56] Injection of PDGF-BB has been shown to increase the mechanical properties of the healing ligament.^[55,57,58] To overcome a potential overload of growth factors after local administration, time-dependent administration of PDGF-BB was investigated recently for tendon healing.^[55,59] It has also been shown that EGF, IGF-1 and PDGF-BB individually stimulate fibroblast proliferation. IGF-1 seems to possess anti-inflammatory functions and also acts as a chemotactic attractant for endothelial cells.^[55,60] TGF- β 1 was originally shown to be involved in chick distal limb tendon formation during embryonic development. After local administration, TGF- β stimulates collagen synthesis and in combination with EGF, stimulates an improved healing of ligaments.^[55,61] There is now ample evidence that growth and differentiation factors 5, 6 and 7 (GDF 5, 6, 7); also termed cartilage-derived morphogenetic proteins 1, 2, 3 [CDMP 1, 2, 3] or BMP 14, 13, 12, respectively and all members of the BMP family of growth factors, affect tendon and ligament formation.^[55] Inactivation of GDF 5 and GDF 6 genes in mice causes defects in ligaments.^[55,62-64] A role for GDF 5, 6 or 7 in tendon or ligament formation has also been demonstrated in that, tendon-like structures result after the ectopic implantation of these factors into subcutaneous or intramuscular sites in adult rats.^[55,65] GDF 5, 6 and 7 were also used successfully in dose-response studies for rat Achilles tendon healing; GDF 7 (BMP 12)-transfected pluripotent mesenchymal stem cells contributed to the healing of a tendon defect.^[55,66-68] The role of TGF- β /BMP family members in tendon/ligament formations was substantiated in a recent study showing that a specific signalling mediator of the TGF- β /BMP family, Smad 8, has tenogenic potential.^[55,69] In conclusion, growth factors from various origins and sources have the capacity to promote tendon healing. However, an understanding of the right time for the administration of growth factors and their dosage is a prerequisite to design effective growth factor therapy.

Gene therapy

Gene therapy delivers genetic material (DNA) to cells, allowing the modification of cellular function by means of viral or nonviral vectors or direct gene transfer.^[70] Gene therapy enables the delivery of individual proteins to specific tissues and cells.^[70-73] Several animal studies have been conducted to investigate the feasibility of gene transfer to tendons.^[70,74] For example, hemagglutinating virus of Japan (HVJ)-liposome constructs were used to deliver β -galactosidase to rat patellar tendons. *In vivo* and *ex vivo* gene transfer techniques have been used as well, as a result of which, sustained gene expression seems to last for about six weeks, possibly long enough for clinical applications.^[70,75,76,77] *Ex vivo* gene transduction is possibly more efficient, but the techniques must be optimized. Gene therapy can also alter the healing environment of tendons in animal models of tendon repair. Adenoviral transduction of focal adhesion kinase (FAK) into partially lacerated chicken flexor tendons resulted in an expected increase in adhesion formation and a twofold increase in the work required for flexion compared with the results in control groups.^[70,78] These differences were significant ($P = 0.001$). While tendon healing was not improved in this study, the results did demonstrate that the healing environment and conditions could be manipulated.^[70,78] Bone morphogenetic protein-12 (BMP-12), the human analog of murine GDF-7257, is found to increase the expression of procollagen types I and III genes in human patellar tenocytes, and it is found at sites of tendon remodelling.^[70,79,80] BMP-12 increases the synthesis of type I collagen by 30% in chicken flexor tenocytes, and the application of tenocytes transfected with the BMP-12 gene to a chicken flexor tendon laceration model resulted in a twofold increase in tensile strength and load to failure after four weeks.^[70,81] Transfer of genes to tendons is feasible, and as the healing environment can be manipulated for up to eight to ten weeks, this may be long enough to be clinically relevant. The above studies were conducted in tendon transfection models; in addition to this, the delivery of substances such as platelet-derived growth factor-B (PDGF-B), BMP-12, and decorin may improve healing of tendinopathy; however, additional research is required.^[70,81-88]

Organizing cells within the scaffold - Tendon engineering by the application of mechanical load

Studies in developmental biology and wound healing have revealed many of the biological events and signals involved in tendon cells and tissue morphogenesis.^[88-90] It is important for tissue engineers to understand these

events as it may be necessary to employ the principles of developmental biology in designing the appropriate microenvironment for tissue regeneration. *In vitro* tissue development may include the application of mechanical loading to precondition the engineered tissue for the *in vivo* mechanical environment. Mechanical stress plays a significant role in modulating cell behavior and has driven the development of mechanical bioreactors for tissue engineering applications.^[89-92] Tendons transmit force from the muscle to the bone and act as a buffer by absorbing external forces to limit muscle damage. Tendons exhibit high mechanical strength, good flexibility, and an optimal level of elasticity to perform their unique role. Tendons are visco-elastic tissues that display stress relaxation and creep. The mechanical behavior of the constituent collagen depends on the number and types of intramolecular and intermolecular bonds.

Experiments have confirmed cell growth and function would be controlled locally through physical distortion of the associated cells or through changes in cytoskeletal tension. Moreover, experimental studies have demonstrated that cultured cells can be switched between different fates including growth, differentiation, apoptosis, directional motility or different stem cell lineages, by modulating cell shape.^[90-93] Kessler *et al.*^[46,94] demonstrated that collagen fibres and tendon cells can be oriented along the direction of the stress and can upregulate synthesis of tissue inhibitor matrix metalloproteinases-1 and -3 as well as of collagen type I, the main component of tendinous extracellular matrix. Moreover, *in vitro* cyclic strain allows an increased production of TGF- β , FGF and PDGF by human tendon fibroblasts.^[46,95] Cyclic stretching of collagen type I matrix seeded with MSCs for 14 days (8 h/day) resulted in the formation of a tendon-like matrix.^[46,96] Expression of collagen types I and III, fibrinectin and elastin genes was found to have increased when compared with nonstretched controls in which no ligament matrix was found.^[46,97] We have observed that nonwoven hyaluronic acid biomaterial allows the development of 3D cultures, which allows tenocyte integration and proliferation. Mechanical traction enhances cell proliferation and their longitudinal alignment [Figures 1 and 2]. The model reproduces *in vivo* tendon healing by preventing differentiation of tenocytes into fibroblasts. Other experiments have demonstrated the beneficial effects of motion and mechanical loading on tenocyte function.^[70,98] Repetitive motion increases DNA content and protein synthesis in human tenocytes in culture.^[70,98]



Figure 1: Bioreactor. We developed a bioreactor able to reproduce a cyclic mechanical stretching onto cell-seeded biomaterials (A). White arrow in (A) points at the electrical connection, in (B) shows a detail of biomaterial anchoring system and in (C) points at stretched biomaterial




Figure 2: Diagram of our *in vitro* experiment. (A) Biomaterial before stretching; (B and C) tenocytes (T) seeded onto biomaterial (B) after 6 days of culture under mechanical cyclic tension; (D-E) cell-biomaterial culture system after 12 days: mechanical stress is a factor that is thought to play an essential role in tissue generation and repair processes. We have observed that cyclic stretching of cells induces various biological responses, including cell proliferation and longitudinal alignment

Even fifteen minutes of cyclic biaxial mechanical strain applied to human tenocytes, results in improved cellular proliferation.^[70,99]

In animal experiments, mechanical stretching has improved the tensile strength, elastic stiffness, weight and cross-sectional area of tendons.^[70,100,101] These effects result from an increase in collagen and extracellular matrix network syntheses by tenocytes. Application of a cyclic load to wounded avian flexor tendons results in the migration of epitendon cells into the wound.^[70,102] In rabbit patellar tendons, application of a 4% strain provides protection against degradation of mechanical stretching by bacterial collagenase.^[70,103]

Clinical studies have shown the benefit of early mobilization following tendon repair, and several postoperative mobilization protocols have been advocated.^[70,104-108] The precise mechanism by which cells respond to load remains to be elucidated.^[70] However, cells must respond

to mechanical and chemical signals in a coordinated fashion. For example, intercellular communication by means of gap junctions is necessary to mount mitogenic and matrigenic responses in *ex vivo* models.^[70] Duration, frequencies and amplitude of loading directly influence cellular response and behavior in many other tissues. Understanding the physiological window for these parameters is critical and represents future challenges of research in tendon tissue engineering.

CONCLUSIONS

Technological improvements in the field of tissue engineering are leading to new potential developments in the approaches being used to treat tendon injuries. An integration of mesenchymal stem cells, growth factors, mechanical stimuli (bioreactor) and bioresorbable polymers can provide a solution for the treatment of difficult tendon injuries.

Despite preliminary *in vitro* and *in vivo* results, several objectives still remain unaccomplished for complete tendon regeneration: i) there is no scaffold able to simultaneously respond to major requirements like biocompatibility, biofunctionality, mechanical properties and processability; ii) cell culture procedures to be performed on scaffolds are not yet satisfactory, often resulting in a low rate of cellular adhesion and of ECM deposition; iii), there is currently a significant gap between *in vitro* results and *in vivo* application of tissue-engineered tendon tissue. Moreover, our knowledge is still limited in the field of growth factor and gene therapy for tendon regeneration, being based only on empirical observations rather than on a thorough understanding of the underlying mechanisms and pathways.^[109] Future research is needed to show that the extracellular matrix produced *in vivo* in response to the cell/growth factor/polymer composites, is effective and functional as a regenerated tissue.

REFERENCES

1. Louie L, Yannas I, Spector M. Tissue engineered tendon. *In: Patrick Jr. C, Mikos A, McIntire L, editors. Frontiers in tissue engineering. New York: Elsevier Science Ltd; 1998. p. 413-42.*
2. Woo SL, Abramowitch SD, Kilger R, Liang R. Biomechanics of knee ligaments: Injury, healing, and repair. *J Biomech* 2006;39:1-20.
3. Kim CW, Pedowitz RA. Part A: Graft choices and the biology of graft healing. *Daniel's Knee Injuries* 2003. p. 435-91.
4. Goulet F, Rancourt D, Cloutier R, Germain L, Poole A, Auger F. Tendons and ligaments. *Principles of tissue engineering* 2000. p. 711-22.
5. Doroski DM, Brink KS, Johnna S. Techniques for biological characterization of tissue-engineered tendon and ligament. *Biomaterials* 2007;28:187-202.
6. Butler D, Awad H. Perspectives on cell and collagen composites for tendon repair. *Clin Orthop Relat Res* 1999;367:324-32.
7. Henshaw D, Attia E, Bhargava E, Hannafin J, Canine AC. Fibroblast integrin expression and cell alignment in response to cyclic tensile strain in three-dimensional collagen gels. *J Orthop Res* 2006;24:481-90.
8. Musahl V, Abramowitch S, Gilbert T, Tsuda E, Wang J, Badylak S, *et al.* The use of porcine small intestinal submucosa to enhance the healing of the medial collateral ligament a functional tissue engineering study in rabbits. *J Orthop Res* 2004;22:214-20.
9. Rodeo SA, Maher SA, Hidaka C. What's new in orthopaedic research. *J Bone J Surg Am* 2004;86:2085-95.
10. Funakoshi T, Majima T, Iwasaki N, Suenaga N, Sawaguchi N, Shimode K, *et al.* Application of tissue engineering techniques for rotator cuff regeneration using a chitosan-based hyaluronan hybrid fiber scaffold. *Am J Sports Med* 2005;33:1193-201.
11. Majima T, Funakoshi T, Iwasaki N, Yamane ST, Harada K, Nonaka S, *et al.* Alginate and chitosan polyion complex hybrid fibers for scaffolds in ligament and tendon tissue engineering. *J Orthop Sci* 2005;10:302-7.
12. Funakoshi T, Majima T, Iwasaki N, Suenaga N, Sawaguchi N, Shimode K, *et al.* Application of tissue engineering techniques for rotator cuff regeneration using a chitosan-based hyaluronan hybrid fiber scaffold. *Am J Sports Med* 2005;33:1193-201.
13. Altman GH, Horan RL, Lu HH, Moreau J, Martin I, Richmond JC, *et al.* Silk matrix for tissue engineered anterior cruciate ligaments. *Biomaterials* 2002;23:4131-41.
14. Chen J, Altman GH, Karageorgiou V, Horan R, Collette A, Volloch V, *et al.* Human bone marrow stromal cell and ligament fibroblast responses on RGD-modified silk fibers. *J Biomed Mater Res A* 2003;67:559-70.
15. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, *et al.* Silk-based biomaterials. *Biomaterials* 2003;24:401-16.
16. Martinek V, Latterman C, Usas A, Abramowitch S, Woo SL, Fu FH, *et al.* Enhancement of tendon-bone integration of anterior cruciate ligament grafts with bone morphogenetic protein-2 gene transfer: A histological and biomechanical study. *J Bone J Surg Am* 2002;84:1123-31.
17. Ahmed Z, Underwood S, Brown RA. Low concentrations of fibrinogen increase cell migration speed on fibronectin/fibrinogen composite cables. *Cell Motil Cytoskeleton* 2000;46: 6-16.
18. Lu HH, Cooper JA, Manuel S, Freeman JW, Attawia MA, Ko FK, *et al.* Anterior cruciate ligament regeneration using braided biodegradable scaffolds: *In vitro* optimization studies. *Biomaterials* 2005;26:4805-16.
19. Vunjak-Novakovic G, Altman G, Horan R, Kaplan DL. Tissue engineering of ligaments. *Annu Rev Biomed Eng* 2004;6:131-56.
20. Ide A, Sakane M, Chen G, Shimojo H, Ushida T, Tateishi T, *et al.* Collagen hybridization with poly(L-lactic acid) braid promotes ligament cell migration. *Mater Sci Eng C* 2001;C17:95-9.
21. Cooper JA, Lu HH, Ko FK, Freeman JW, Laurencin CT. Fiberbased tissue-engineered scaffold for ligament replacement: Design considerations and *in vitro* evaluation. *Biomaterials* 2004;26:1523-32.
22. Qin TW, Yang ZM, Wu ZZ, Xie HQ, Qin J, Cai SX. Adhesion strength of human tenocytes to extracellular matrix componentmodified poly(DL-lactide-co-glycolide) substrates. *Biomaterials* 2005;26:6635-42.
23. Auger FA, Rouabhia M, Goulet F, Berthod F, Moulin V, Germain L. Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: Clinical and fundamental. *Med Biol Eng Comput* 1998;6:801-12.
24. Huang D, Chang TR, Aggarwal A, Lee RC, Ehrlich HP. Mechanisms and dynamics of mechanical strengthening in ligament-equivalent fibroblast-populated collagen matrices. *Ann Biomed Eng* 1993;3:289-305.
25. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential *in vitro*. *Proc Nat Acad Sci USA* 1979;3:1274-8.
26. Klebe RJ, Caldwell H, Milam S. Cells transmit spatial information by orienting collagen fibers. *Matrix* 1989;6:451-8.
27. Nishiyama T, Tsunenaga M, Akutsu N, Horii I, Nakayama Y, Adac E, *et al.* Dissociation of actin microfilament organization from acquisition and maintenance of elongated shape of human dermal fibroblasts in three-dimensional collagen gel. *Matrix* 1993;6:447-55.
28. Ben-Ze'ev A, Farmer SR, Penman S. Protein synthesis requires cell-surface contact while nuclear events respond to cell shape in anchorage-dependent fibroblasts. *Cell* 1980;2:365-72.
29. Harris AK, Stopak D, Wild P. Fibroblast traction as a mechanism for collagen morphogenesis. *Nature* 1981;290:249-51.
30. Maciera-Coelho A, Garcia-Giralt E, Adrian M. Changes in lysosomal associated structures in human fibroblasts kept in resting phase. *Proc Soc Exp Biol Med* 1971;2:712-8.
31. Bellincampi LD, Closkey RF, Prasad R, Zawadsky JP, Dunn MG. Viability of fibroblast-seeded ligament analogs after autogenous implantation. *J Orthop Res* 1998;4:414-20.
32. Dunn MG, Liesch JB, Tiku ML, Zawadsky JP. Development of fibroblast-seeded ligament analogs for ACL reconstruction. *J Biomed Mater Res* 1995;11:1363-71.
33. Brody GA, Eisinger M, Arnoczky SP, Warren RF. *In vitro* fibroblast seeding of prosthetic anterior cruciate ligaments: A preliminary study. *Am J Sports Med* 1988;3:203-8.
34. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. *Biomaterials* 1996;2:93-102.
35. Gherzi R, Cavallaro AM, Lodi V, Missere M, Violante FS. Repetitive movement of the upper limbs: Results of a current exposure evaluation and a clinical investigation in workers employed in the preparation of pork meat in the province of Modena. *Med Lav* 1996;6:656-74.
36. Chvapil M, Speer DP, Holubec H, Chvapil TA, King DH. Collagen fibers as a temporary scaffold for replacement of ACL in goats. *J Biomed Mater Res* 1993;3:313-25.
37. Infeld MD, Brennan JA, Davis PB. Human tracheobronchial epithelial cells direct migration of lung fibroblasts in three-dimensional collagen gels. *Am J Physiol* 1992;5:L535-41.
38. Gentleman E, Lay AN, Dickerson DA, Nauman EA, Livesay GA, Dee KC. Mechanical characterization of collagen fibers and scaffolds for tissue engineering. *Biomaterials* 2003;21:3805-13.
39. Sato M, Maeda M, Kurosawa H, Inoue Y, Yamauchi Y, Iwase H.

- Reconstruction of rabbit Achilles tendon with three bioabsorbable materials: Histological and biomechanical studies. *J Orthop Sci* 2000;3:256-67.
40. Wasserman AJ, Kato YP, Christiansen D, Dunn MG, Silver FH. Achilles tendon replacement by a collagen fiber prosthesis: Morphological evaluation of neotendon formation. *Scanning Microsc* 1989;3:1183-97.
 41. Laurencin CT, Ambrosio AM, Borden MD, Cooper JA Jr. Tissue engineering: Orthopedic applications. *Annu Rev Biomed Eng* 1999;1:19-46.
 42. Kisiday JD, Jin M, DiMicco MA, Kurz B, Grodzinsky AJ. Effects of dynamic compressive loading on chondrocyte biosynthesis in self-assembling peptide scaffolds. *J Biomech* 2004;5:595-604.
 43. Altman G, Horan R, Martin I, Farhadi J, Stark P, Volloch V, *et al.* Cell differentiation by mechanical stress. *FASEBJ* 2002;16:270-2.
 44. Musahl V, Abramowitch SD, Gilbert TW, Tsuda E, Wang JH, Badyalak SF. The use of porcine small intestinal submucosa to enhance the healing of the medial collateral ligament a functional tissue engineering study in rabbits. *J Orthop Res* 2004;1:214-20.
 45. Li F, Li B, Wang QM, Wang JH. Cell shape regulates collagen type I expression in human tendon fibroblasts. *Cell Motil Cytoskeleton* 2008;31:1-10.
 46. Bagnaninchi PO, Yang Y, El Hai AJ, Maffulli N. Tissue engineering for tendon repair. *Br J Sports Med* 2007;41:e10.
 47. Yao L, Bestwick CS, Bestwick LA, Maffulli N, Aspden RM. Phenotypic drift in human tenocyte culture. *Tissue Eng* 2006;12:1843-9.
 48. Cao D, Liu W, Wei X, Xu F, Cui L, Cao Y. *In vitro* tendon engineering with avian tenocytes and polyglycolic acids: A preliminary report. *Tissue Eng* 2006;12:1369-77.
 49. Awad HA, Butler DL, Boivin GP, Smith FN, Malaviya P, Huijbregtse B, *et al.* Autologous mesenchymal stem cell-mediated repair of tendon. *Tissue Eng* 1999;5:267-77.
 50. Awad HA, Butler DL, Harris MT, Ibrahim RE, Wu Y, Young RG, *et al.* *In vitro* characterization of mesenchymal stem cell-seeded collagen scaffolds for tendon repair: Effects of initial seeding density on contraction kinetics. *J Biomed Mater Res* 2000;51:233-40.
 51. Ge Z, Gohm J, Lee E. Selection of cell source for ligament tissue engineering. *Cell Transplant* 2005;14:573-83.
 52. Kall S, Nöth U, Reimers K, Choi CY, Muehlberger T, Allmeling C, *et al.* *In vitro* fabrication of tendon substitutes using human mesenchymal stem cells and a collagen type I gel. *Handchir Mikrochir Plast Chir* 2004;36:205-11.
 53. Kryger GS, Chong AK, Costa M, Pham H, Bates SJ, Chang J. A comparison of tenocytes and mesenchymal stem cells for use in flexor tendon tissue engineering. *J Hand Surg* 2007;32:597-605.
 54. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, *et al.* Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. *J Clin Invest* 1997;100:321-30.
 55. Hoffmann A, Gross G. Tendon and ligament engineering: From cell biology to *in vivo* application. *Regen Med* 2006;1:563-74.
 56. Chan BP, Fu S, Qin L, Lee K, Rolf CG, Chan K. Effects of basic fibroblast growth factor (bFGF) on early stages of tendon healing: A rat patellar tendon model. *Acta Orthop Scand* 2000;71:513-8.
 57. Hildebrand KA, Woo SL, Smith DW, Allen CR, Deie M, Taylor BJ, *et al.* The effects of platelet-derived growth factor-BB on healing of the rabbit medial collateral ligament: An *in vivo* study. *Am J Sports Med* 1998;26:549-54.
 58. Batten ML, Hansen JC, Dahners LE. Influence of dosage and timing of application of platelet-derived growth factor on early healing of the rat medial collateral ligament. *J Orthop Res* 1996;14:736-41.
 59. Schmidt CC, Georgescu HI, Kwok CK, Blomstrom GL, Engle CP, Larkin LA, *et al.* Effect of growth factors on the proliferation of fibroblasts from the medial collateral and anterior cruciate ligaments. *J Orthop Res* 1995;13:184-90.
 60. Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, Campbell PG. Insulin-like growth factor I accelerates functional recovery from Achilles tendon injury in a rat model. *Am J Sports Med* 1999;27:363-9.
 61. D'Souza D, Patel K. Involvement of long and short-range signalling during early tendon development. *Anat Embryol (Berl)* 1999;200:367-75.
 62. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee SJ. Limb alterations in brachypodism mice due to mutations in a new member of the TGF- β -superfamily. *Nature* 1994;368:639-43.
 63. Settle SH Jr, Rountree RB, Sinha A, Thacker A, Higgins K, Kingsley DM. Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse *Gdf6* and *Gdf5* genes. *Dev Biol* 2003;254:116-30.
 64. Chhabra A, Tsou D, Clark RT, Gaschen V, Hunziker EB, Mikic B. GDF-5 deficiency in mice delays Achilles tendon healing. *J Orthop Res* 2003;21:826-35.
 65. Mikic B, Schalet BJ, Clark RT, Gaschen V, Hunziker EB. GDF-5 deficiency in mice alters the ultrastructure, mechanic al properties and composition of the Achilles tendon. *J Orthop Res* 2001;19:365-71.
 66. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, *et al.* Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF- β gene family. *J Clin Invest* 1997;100:321-30.
 67. Forslund C, Rueger D, Aspenberg P. A comparative dose-response study of cartilage-derived morphogenetic protein (CDMP)-1, -2 and -3 for tendon healing in rats. *J Orthop Res* 2003;21:617-21.
 68. Virchenko O, Fahlgren A, Skoglund B, Aspenberg P. CDMP-2 injection improves early tendon healing in a rabbit model for surgical repair. *Scand J Med Sci Sports* 2005;15:260-4.
 69. Lou J, Tu Y, Burns M, Silva MJ, Manske P. BMP-12 gene transfer augmentation of lacerated tendon repair. *J Orthop Res* 2001;19:1199-202.
 70. Sharma P, Maffulli N. Tendon injury and tendinopathy: Healing and repair. *J Bone Joint Surg Am* 2005;87:187-202.
 71. Nakamura N, Timmermann SA, Hart DA, Kaneda Y, Shrive NG, Shino K, *et al.* A comparison of *in vivo* gene delivery methods for antisense therapy in ligament healing. *Gene Ther* 1998;5:1455-61.
 72. Nakamura N, Shino K, Natsuume T, Horibe S, Matsumoto N, Kaneda Y, *et al.* Early biological effect of *in vivo* gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament. *Gene Ther* 1998;5:1165-70.
 73. Hannallah D, Peterson B, Lieberman JR, Fu FH, Huard J. Gene therapy in orthopaedic surgery. *Instr Course Lect* 2003;52:753-68.
 74. Nakamura N, Horibe S, Matsumoto N, Tomita T, Natsuume T, Kaneda Y, *et al.* Transient introduction of a foreign gene into healing rat patellar ligament. *J Clin Invest* 1996;97:226-31.
 75. Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH. Gene transfer to the rabbit patellar tendon: Potential for genetic enhancement of tendon and ligament healing. *Gene Ther* 1996;3:1089-93.
 76. Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH. Gene transfer to the patellar tendon. *Knee Surg Sports Traumatol Arthrosc* 1997;5:118-23.
 77. Lou J, Kubota H, Hotokezaka S, Ludwig FJ, Manske PR. *In vivo* gene transfer and over-expression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. *J Orthop Res* 1997;15:911-8.

78. Wolfman NM, Celeste AJ, Cox K. Preliminary characterization of the biological activities of rhBMP-12. *J Bone Miner Res* 1995;10:S148.
79. Fu SC, Wong YP, Chan BP, Pau HM, Cheuk YC, Lee KM, *et al.* The roles of bone morphogenetic protein (BMP) 12 in stimulating the proliferation and matrix production of human patellar tendon fibroblasts. *Life Sci* 2003;72:2965-74.
80. Lou J, Tu Y, Burns M, Silva MJ, Manske P. BMP-12 gene transfer augmentation of lacerated tendon repair. *J Orthop Res* 2001;19:1199-202.
81. Nakamura N, Shino K, Natsuume T, Horibe S, Matsumoto N, Kaneda Y, *et al.* Early biological effect of *in vivo* gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament. *Gene Ther* 1998;5:1165-70.
82. Marchant JK, Hahn RA, Linsenmayer TF, Birk DE. Reduction of type V collagen using a dominant-negative strategy alters the regulation of fibrillogenesis and results in the loss of corneal-specific fibril morphology. *J Cell Biol* 1996;135:1415-26.
83. Adachi E, Hayashi T. *In vitro* formation of hybrid fibrils of type V collagen and type I collagen: Limited growth of type I collagen into thick fibrils by type V collagen. *Connect Tissue Res* 1986;14:257-66.
84. Niyibizi C, Kavalkovich K, Yamaji T, Woo SL. Type V collagen is increased during rabbit medial collateral ligament healing. *Knee Surg Sports Traumatol Arthrosc* 2000;8:281-5.
85. Shimomura T, Jia F, Niyibizi C, Woo SL. Antisense oligonucleotides reduce synthesis of procollagen alpha1 (V) chain in human patellar tendon fibroblasts: Potential application in healing ligaments and tendons. *Connect Tissue Res* 2003;44:167-72.
86. Hart DA, Nakamura N, Marchuk L, Hiraoka H, Boorman R, Kaneda Y, *et al.* Complexity of determining cause and effect *in vivo* after antisense gene therapy. *Clin Orthop Relat Res* 2000;379:S242-51.
87. Nakamura N, Timmermann SA, Hart DA, Kaneda Y, Shrive NG, Shino K, *et al.* A comparison of *in vivo* gene delivery methods for antisense therapy in ligament healing. *Gene Ther* 1998;5:1455-61.
88. Nakamura N, Hart DA, Boorman RS, Kaneda Y, Shrive NG, Marchuk LL, *et al.* Decorin antisense gene therapy improves functional healing of early rabbit ligament scar with enhanced collagen fibrillogenesis *in vivo*. *J Orthop Res* 2000;18:517-23.
89. Ingber DE. Mechanical control of tissue morphogenesis during embryological development. *Int J Dev Biol* 2006;50:255-66.
90. Barkhausen T, van Griensven M, Zeichen J, Bosch U. Modulation of cell functions of human tendon fibroblasts by different repetitive cyclic mechanical stress patterns. *Exp Toxicol Pathol* 2003;55:153-8.
91. Brown RA, Prajapati R, McGrouther DA, Yannas IV, Eastwood M. Tensional homeostasis in dermal fibroblasts: Mechanical responses to mechanical loading in three-dimensional substrates. *J Cell Physiol* 1998;175:323-32.
92. Wang JH, Yang G, Li Z, Shen W. Fibroblast responses to cyclic mechanical stretching depend on cell orientation to the stretching direction. *J Biomech* 2004;37:573-6.
93. Schulze-Tanzil G, Mobasher A, Clegg PD, Sendzik J, John T, Shakibaei M. Cultivation of human tenocytes in high-density culture. *Histochem Cell Biol* 2004;122:219-28.
94. Kessler D, Dethlefsen S, Haase I, Plomann M, Hirche F, Krieg T, *et al.* Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. *J Biol Chem* 2001;276:36575-85.
95. Slutek M, Van GM, Zeichen J, Brauer N, Bosch U. Cyclic mechanical stretching modulates secretion pattern of growth factors in human tendon fibroblasts. *Eur J Appl Physiol* 2001;86:48-52.
96. Zeichen J, Van GM, Bosch U. The proliferative response of isolated human tendon fibroblasts to cyclic biaxial mechanical strain. *Am J Sport Med* 2000;28:888-92.
97. Yang G, Crawford RC, Wang JH. Proliferation and collagen production of human patellar tendon fibroblasts in response to cyclic uniaxial stretching in serum-free conditions. *J Biomech* 2004;37:1543-50.
98. Almekinders LC, Baynes AJ, Bracey LW. An *in vitro* investigation into the effects of repetitive motion and nonsteroidal anti-inflammatory medication on human tendon fibroblasts. *Am J Sports Med* 1995;23:119-23.
99. Zeichen J, van Griensven M, Bosch U. The proliferative response of isolated human tendon fibroblasts to cyclic biaxial mechanical strain. *Am J Sports Med* 2000;28:888-92.
100. Kannus P, Józsa KP, Renstrom P. The effects of training, immobilization and remobilization on musculoskeletal tissue, 1: Training and immobilization. *Scand J Med Sci Sports* 1992;2:100-18.
101. Kannus P, Józsa L, Natri A, Jarvinen M. Effects of training, immobilization and remobilization on tendons. *Scand J Med Sci Sports* 1997;7:67-71.
102. Tanaka H, Manske PR, Pruitt DL, Larson BJ. Effect of cyclic tension on lacerated flexor tendons *in vitro*. *J Hand Surg Am* 1995;20:467-73.
103. Nabeshima Y, Grood ES, Sakurai A, Herman JH. Uniaxial tension inhibits tendon collagen degradation by collagenase *in vitro*. *J Orthop Res* 1996;14:123-30.
104. Buckwalter JA. Activity vs rest in the treatment of bone, soft tissue and joint injuries. *Iowa Orthop J* 1995;15:29-42.
105. Buckwalter JA. Effects of early motion on healing of musculoskeletal tissues. *Hand Clin* 1996;12:13-24.
106. Chow JA, Thomes LJ, Dovel S, Monsivais J, Milnor WH, Jackson JP. Controlled motion rehabilitation after flexor tendon repair and grafting: A multi-centre study. *J Bone Joint Surg Br* 1988;70:591-5.
107. Cullen KW, Tolhurst P, Lang D, Page RE. Flexor tendon repair in zone 2 followed by controlled active mobilisation. *J Hand Surg Br* 1989;14:392-5.
108. Elliot D, Moiemens NS, Flemming AF, Harris SB, Foster AJ. The rupture rate of acute flexor tendon repairs mobilized by the controlled active motion regimen. *J Hand Surg Br* 1994;19:607-12.
109. Liu Y, Ramanath HS, Wang DA. Tendon tissue engineering using scaffold enhancing strategies. *Trends Biotech* 2008;26:201-9.

Source of Support: Nil. **Conflict of Interest:** None declared.